Chambers Review
Provided by Chambers
Life Sciences - Brazil
What the Team is Known For
BRZ - Barbosa, Raimundo, Gontijo, Câmara & Zanotta Advogados's life sciences practice is particularly noted for its market knowledge and precise regulatory advice. It is regularly seen representing pharmaceutical labs, as well as industry associations, in appeals addressed to health agencies such as ANS and Anvisa.
Strengths
BRZ has always shown know-how when handling sensitive matters and brought appropriate solutions to the issues we presented.
BRZ is a firm with deep knowledge of the pharmaceutical market and good relations with the Ministry of Health.
In the face of a constantly evolving regulatory landscape, BRZ shows a great capacity for adaptation and innovation, always seeking new ways to accelerate the release of new products.
Notable practitioners
Aline Mendes Coelho is a life sciences practitioner highly regarded for her prowess in administrative contentious work. A go-to lawyer for pharmaceutical companies, she's regularly retained to assist with matters related to medicine approval and pricing.
Besides excellent analytical and technical skills, Aline has a strong commitment to deadlines and quality. Her collaborative and detail-oriented approach makes her support essential to us.
Aline Coelho adds a lot to the discussions with her knowledge of the pharmaceutical area. Her flexibility and sense of urgency are strengths.
Aline knows a lot about health regulations. She's also highly available and prepared to help.
Jorge Raimundo has vast experience in the life sciences market, consistently earning praise from clients. His work includes providing advice to clients on matters involving ANVISA.
Jorge Raimundo stands out with his remarkable expertise, which few professionals in this industry possess.
Jorge Raimundo's in-depth knowledge of the market and his ability to navigate regulatory and institutional environments make him a distinguished professional.
Jorge is a recognised authority in the pharmaceutical industry and rare disease market.